Treatment Regimen for Tuberculosis

Initial Phase (First 2 Months)

The American Thoracic Society recommends a 2-month initial phase of isoniazid, rifampin, pyrazinamide, and ethambutol to maximize effectiveness and prevent the development of drug resistance, especially in areas where isoniazid resistance is >4% 1, 3
The Centers for Disease Control and Prevention suggests the following dosages for the initial 2-month phase: isoniazid (5 mg/kg daily), rifampin (10 mg/kg daily), pyrazinamide (35 mg/kg daily for patients <50 kg; 2.0 g daily for patients >50 kg), and ethambutol (15 mg/kg daily) 1, 4
Ethambutol may be discontinued once drug susceptibility testing confirms that the organism is fully susceptible to isoniazid and rifampin, as recommended by the American Academy of Family Physicians 1, 2

The American College of Chest Physicians recommends continuation of treatment with isoniazid and rifampin for an additional 4 months after the initial 2-month phase 1, 4
The World Health Organization suggests that this continuation phase can be administered daily or 2-3 times weekly under directly observed therapy (DOT) 1, 2

The Centers for Disease Control and Prevention recommends a 7-month continuation phase (total 9 months) for patients with cavitary pulmonary TB with positive sputum cultures after 2 months of treatment, or for those with initial treatment that did not include pyrazinamide, or for HIV-positive patients with CD4+ counts <100 cells/mm³ 1, 2, 5
For isoniazid-resistant TB, the American Thoracic Society suggests a regimen of rifampin, ethambutol, pyrazinamide, and a later-generation fluoroquinolone for 6 months 6
For multidrug-resistant TB (MDR-TB), individualized regimens based on drug susceptibility testing should be used under the guidance of TB specialists, as recommended by the World Health Organization 6

The Centers for Disease Control and Prevention recommends HIV testing for all TB patients within 2 months of TB diagnosis, and standard TB regimens are generally effective for HIV-positive patients, but treatment duration may need to be extended 3, 5
For HIV-positive patients with CD4+ counts <100 cells/mm³, daily therapy is recommended during the intensive phase followed by daily or three times weekly therapy during the continuation phase, as suggested by the National Institutes of Health 5

The American Thoracic Society strongly recommends directly observed therapy (DOT) as the central element in a comprehensive, patient-centered approach to case management 1
The initial phase may be given daily throughout, daily for 2 weeks and then twice weekly for 6 weeks, or three times weekly throughout, as recommended by the Centers for Disease Control and Prevention 1

The American College of Chest Physicians recommends that all TB cases should be promptly reported to the local public health department, and sputum cultures should be obtained regularly to monitor treatment response 1, 3
Drug susceptibility testing should be performed on initial isolates from all patients, as suggested by the World Health Organization 1